Gram positive Bacterial Infections Market size is expected to grow at a CAGR of 2.10% during the forecast period and the market size is expected to reach nearly US$ 64.42 Bn. by 2029.Gram-positive Bacterial Infections Market:
Bacterial infections are a major cause of illness and are generally acquired through various sources. Based on staining, bacteria are classified into two types: gram-positive and gram-negative. Gram-positive bacteria retain gram stain and hence, are observed under the microscope as violet purple colored stains. They are a major class of bacteria and cause various infections in humans. Gram-positive bacterial infection drugs act against gram-positive bacterial infections such as MRSA infections, sinusitis, pneumonia and others which we have covered in the report.The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.To know about the Research Methodology :- Request Free Sample Report
Objective of the Report:
The objective of the report is to present a comprehensive analysis of Global Gram-positive Bacterial Infections Market including all the stakeholders in the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Gram-positive Bacterial Infections Market dynamics, structure by analysing the market segments and project the Global Gram-positive Bacterial Infections Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product Portfolio, Growth strategies, and Regional presence in the Global Gram-positive Bacterial Infections Market make the report investor’s guide. The market for the Global Gram-positive Bacterial Infections is expanding rapidly, counting to an increase in the number of cases of gram-positive bacterial infections and a significant rise in antibacterial resistance. Increased government initiatives and funding for R&D activities & newer bacterial infection treatment and infection control in healthcare settings is also a key factors driving the market globally.Gram-Positive Bacterial Infections Market Dynamics:
Most infections due to Gram-Positive Organisms can be treated with quite a small number of antibiotics. But rapid increase in number of this infections is booming the Global Gram-positive Bacterial Infections Market. For understanding Market dynamics more closely, attributes like Drivers, Restraints, Opportunities, and Challenges are studied more closely in report. Gram-Positive Bacterial Infections Market By Disease Type: Methicillin-resistant Staphylococcus aureus (MRSA) refers to a group of Gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. MRSA is any strain of Staphylococcus aureus that has developed, through horizontal gene transfer and natural selection, multiple drug resistance to beta-lactam antibiotics MRSA is common in hospitals, prisons, and nursing homes, where people with open wounds, invasive devices such as catheters, and weakened immune systems are at greater risk of hospital-acquired infection. MRSA began as a hospital-acquired infection, but has become community-acquired, as well as livestock-acquired. Major players operating in the market are focusing on clinical collaboration and commercial expansion to tap several opportunities present in the market. Stringent governmental regulation makes this market tough for small players. Small player in the market are launching several bio-similar products in order to satisfy increasing demand from the emerging economies of the globe.Gram-Positive Bacterial Infections Market Scope:Inquire before buying
Global Grampositive Bacterial Infections Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US$ 55.70 Bn. Forecast Period 2023 to 2029 CAGR: 2.10% Market Size in 2029: US$ 64.42 Bn. Segments Covered: by Disease Pneumonia Sepsis Sinusitis Cellulitis Otitis Pharyngitis Impetigo by Drug Type Antibiotic Antifungal Others by Route of Administration Enteral Parenteral by Distribution Channel Hospital Pharmacies Drug Stores Retail Pharmacies Gram-Positive Bacterial Infections Market, Region Analysis
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key Players:
1. ALLERGAN 2. AstraZeneca 3. Bayer AG 4. GlaxoSmithkline plc. 5. Merck & Co.,Inc. 6. NovaBiotics Ltd 7. Novartis AG 8. Pfizer Inc. 9. Sanofi 10.Theravance Biopharma 11.Bristol-Myers Squibb Company 12.Basilea Pharmaceuticals Ltd. 13.Aphios Corporation 14.GSK plc 15.TAXIS Pharmaceuticals, Inc., Frequently Asked Questions: 1. Which region has the largest share in Global Grampositive Bacterial Infections Market? Ans: Asia Pacific region held the highest share in 2022. 2. What is the growth rate of Global Grampositive Bacterial Infections Market? Ans: The Global Grampositive Bacterial Infections Market is expected to growing at a CAGR of 2.10% during forecast period 2023-2029. 3. What is scope of the Global Grampositive Bacterial Infections market report? Ans: Global Grampositive Bacterial Infections Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Grampositive Bacterial Infections market? Ans: The important key players in the Global Grampositive Bacterial Infections Market are – ALLERGAN, AstraZeneca, Bayer AG, GlaxoSmithkline plc., Merck & Co.,Inc., NovaBiotics Ltd, Novartis AG, Pfizer Inc., Sanofi, Theravance Biopharma, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Aphios Corporation, GSK plc, TAXIS Pharmaceuticals, Inc., and. 5. What is the study period of this market? Ans: The Global Grampositive Bacterial Infections Market is studied from 2022 to 2029.
Global Gram-positive Bacterial Infections Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Gram Positive Bacterial Infections Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Gram Positive Bacterial Infections Market Analysis and Forecast 6.1. Gram Positive Bacterial Infections Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gram Positive Bacterial Infections Market Analysis and Forecast, by Disease 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Gram Positive Bacterial Infections Market Value Share Analysis, by Disease 7.4. Global Gram Positive Bacterial Infections Market Size (US$ Bn) Forecast, by Disease 7.5. Global Gram Positive Bacterial Infections Market Analysis, by Disease 7.6. Global Gram Positive Bacterial Infections Market Attractiveness Analysis, by Disease 8. Global Gram Positive Bacterial Infections Market Analysis and Forecast, by Drug Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Gram Positive Bacterial Infections Market Value Share Analysis, by Drug Type 8.4. Global Gram Positive Bacterial Infections Market Size (US$ Bn) Forecast, by Drug Type 8.5. Global Gram Positive Bacterial Infections Market Analysis, by Drug Type 8.6. Global Gram Positive Bacterial Infections Market Attractiveness Analysis, by Drug Type 9. Global Gram Positive Bacterial Infections Market Analysis and Forecast, Route of Administration 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Gram Positive Bacterial Infections Market Value Share Analysis, Route of Administration 9.4. Global Gram Positive Bacterial Infections Market Size (US$ Bn) Forecast, Route of Administration 9.5. Global Gram Positive Bacterial Infections Market Analysis, Route of Administration 9.6. Global Gram Positive Bacterial Infections Market Attractiveness Analysis, Route of Administration 10. Global Gram Positive Bacterial Infections Market Analysis and Forecast, by Distribution Channel 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Gram Positive Bacterial Infections Market Value Share Analysis, by Distribution Channel 10.4. Global Gram Positive Bacterial Infections Market Size (US$ Bn) Forecast, by Distribution Channel 10.5. Global Gram Positive Bacterial Infections Market Analysis, by Distribution Channel 10.6. Global Gram Positive Bacterial Infections Market Attractiveness Analysis, by Distribution Channel 11. Gram Positive Bacterial Infections Market Analysis, by Region 11.1. Gram Positive Bacterial Infections Market Value Share Analysis, by Region 11.2. Gram Positive Bacterial Infections Market Size (US$ Bn) Forecast, by Region 11.3. Gram Positive Bacterial Infections Market Attractiveness Analysis, by Region 12. North America Gram Positive Bacterial Infections Market Analysis 12.1. Key Findings 12.2. North America Gram Positive Bacterial Infections Market Overview 12.3. North America Gram Positive Bacterial Infections Market Value Share Analysis, by Disease 12.4. North America Gram Positive Bacterial Infections Market Forecast, by Disease 12.4.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 12.4.2. Pneumonia 12.4.3. Sepsis 12.4.4. Sinusitis 12.4.5. Cellulitis 12.4.6. Otitis 12.4.7. Pharyngitis 12.4.8. Impetigo 12.5. North America Gram Positive Bacterial Infections Market Value Share Analysis, by Drug Type 12.6. North America Gram Positive Bacterial Infections Market Forecast, by Drug Type 12.6.1. Antibiotic 12.6.2. Antifungal 12.6.3. Others 12.7. North America Gram Positive Bacterial Infections Market Value Share Analysis, Route of Administration 12.8. North America Gram Positive Bacterial Infections Market Forecast, Route of Administration 12.8.1. Enteral 12.8.2. Parenteral 12.9. North America Gram Positive Bacterial Infections Market Value Share Analysis, by Distribution Channel 12.10. North America Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 12.10.1. Hospital Pharmacies 12.10.2. Drug Stores 12.10.3. Retail Pharmacies 12.11. North America Gram Positive Bacterial Infections Market Value Share Analysis, by Country 12.12. North America Gram Positive Bacterial Infections Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Gram Positive Bacterial Infections Market Analysis, by Country 12.14. U.S. Gram Positive Bacterial Infections Market Forecast, by Disease 12.14.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 12.14.2. Pneumonia 12.14.3. Sepsis 12.14.4. Sinusitis 12.14.5. Cellulitis 12.14.6. Otitis 12.14.7. Pharyngitis 12.14.8. Impetigo 12.15. U.S. Gram Positive Bacterial Infections Market Forecast, by Drug Type 12.15.1. Antibiotic 12.15.2. Antifungal 12.15.3. Others 12.16. U.S. Gram Positive Bacterial Infections Market Forecast, Route of Administration 12.16.1. Enteral 12.16.2. Parenteral 12.17. U.S. Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Drug Stores 12.17.3. Retail Pharmacies 12.18. Canada Gram Positive Bacterial Infections Market Forecast, by Disease 12.18.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 12.18.2. Pneumonia 12.18.3. Sepsis 12.18.4. Sinusitis 12.18.5. Cellulitis 12.18.6. Otitis 12.18.7. Pharyngitis 12.18.8. Impetigo 12.19. Canada Gram Positive Bacterial Infections Market Forecast, by Drug Type 12.19.1. Antibiotic 12.19.2. Antifungal 12.19.3. Others 12.20. Canada Gram Positive Bacterial Infections Market Forecast, Route of Administration 12.20.1. Enteral 12.20.2. Parenteral 12.21. Canada Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 12.21.1. Hospital Pharmacies 12.21.2. Drug Stores 12.21.3. Retail Pharmacies 12.22. North America Gram Positive Bacterial Infections Market Attractiveness Analysis 12.22.1. By Disease 12.22.2. By Drug Type 12.22.3. Route of Administration 12.22.4. By Distribution Channel 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Gram Positive Bacterial Infections Market Analysis 13.1. Key Findings 13.2. Europe Gram Positive Bacterial Infections Market Overview 13.3. Europe Gram Positive Bacterial Infections Market Value Share Analysis, by Disease 13.4. Europe Gram Positive Bacterial Infections Market Forecast, by Disease 13.4.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 13.4.2. Pneumonia 13.4.3. Sepsis 13.4.4. Sinusitis 13.4.5. Cellulitis 13.4.6. Otitis 13.4.7. Pharyngitis 13.4.8. Impetigo 13.5. Europe Gram Positive Bacterial Infections Market Value Share Analysis, by Drug Type 13.6. Europe Gram Positive Bacterial Infections Market Forecast, by Drug Type 13.6.1. Antibiotic 13.6.2. Antifungal 13.6.3. Others 13.7. Europe Gram Positive Bacterial Infections Market Value Share Analysis, Route of Administration 13.8. Europe Gram Positive Bacterial Infections Market Forecast, Route of Administration 13.8.1. Enteral 13.8.2. Parenteral 13.9. Europe Gram Positive Bacterial Infections Market Value Share Analysis, by Distribution Channel 13.10. Europe Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 13.10.1. Hospital Pharmacies 13.10.2. Drug Stores 13.10.3. Retail Pharmacies 13.11. Europe Gram Positive Bacterial Infections Market Value Share Analysis, by Country 13.12. Europe Gram Positive Bacterial Infections Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Gram Positive Bacterial Infections Market Analysis, by Country 13.14. Germany Gram Positive Bacterial Infections Market Forecast, by Disease 13.14.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 13.14.2. Pneumonia 13.14.3. Sepsis 13.14.4. Sinusitis 13.14.5. Cellulitis 13.14.6. Otitis 13.14.7. Pharyngitis 13.14.8. Impetigo 13.15. Germany Gram Positive Bacterial Infections Market Forecast, by Drug Type 13.15.1. Antibiotic 13.15.2. Antifungal 13.15.3. Others 13.16. Germany Gram Positive Bacterial Infections Market Forecast, Route of Administration 13.16.1. Enteral 13.16.2. Parenteral 13.17. Germany Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Drug Stores 13.17.3. Retail Pharmacies 13.18. U.K. Gram Positive Bacterial Infections Market Forecast, by Disease 13.18.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 13.18.2. Pneumonia 13.18.3. Sepsis 13.18.4. Sinusitis 13.18.5. Cellulitis 13.18.6. Otitis 13.18.7. Pharyngitis 13.18.8. Impetigo 13.19. U.K. Gram Positive Bacterial Infections Market Forecast, by Drug Type 13.19.1. Antibiotic 13.19.2. Antifungal 13.19.3. Others 13.20. U.K. Gram Positive Bacterial Infections Market Forecast, Route of Administration 13.20.1. Enteral 13.20.2. Parenteral 13.21. U.K. Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 13.21.1. Hospital Pharmacies 13.21.2. Drug Stores 13.21.3. Retail Pharmacies 13.22. France Gram Positive Bacterial Infections Market Forecast, by Disease 13.22.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 13.22.2. Pneumonia 13.22.3. Sepsis 13.22.4. Sinusitis 13.22.5. Cellulitis 13.22.6. Otitis 13.22.7. Pharyngitis 13.22.8. Impetigo 13.23. France Gram Positive Bacterial Infections Market Forecast, by Drug Type 13.23.1. Antibiotic 13.23.2. Antifungal 13.23.3. Others 13.24. France Gram Positive Bacterial Infections Market Forecast, Route of Administration 13.24.1. Enteral 13.24.2. Parenteral 13.25. France Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 13.25.1. Hospital Pharmacies 13.25.2. Drug Stores 13.25.3. Retail Pharmacies 13.26. Italy Gram Positive Bacterial Infections Market Forecast, by Disease 13.26.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 13.26.2. Pneumonia 13.26.3. Sepsis 13.26.4. Sinusitis 13.26.5. Cellulitis 13.26.6. Otitis 13.26.7. Pharyngitis 13.26.8. Impetigo 13.27. Italy Gram Positive Bacterial Infections Market Forecast, by Drug Type 13.27.1. Antibiotic 13.27.2. Antifungal 13.27.3. Others 13.28. Italy Gram Positive Bacterial Infections Market Forecast, Route of Administration 13.28.1. Enteral 13.28.2. Parenteral 13.29. Italy Gram Positive Bacterial Infections Market Forecast, by Distribution Channel Hospital Pharmacies 13.30. Drug Stores 13.31. Retail Pharmacies 13.32. Spain Gram Positive Bacterial Infections Market Forecast, by Disease 13.32.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 13.32.2. Pneumonia 13.32.3. Sepsis 13.32.4. Sinusitis 13.32.5. Cellulitis 13.32.6. Otitis 13.32.7. Pharyngitis 13.32.8. Impetigo 13.33. Spain Gram Positive Bacterial Infections Market Forecast, by Drug Type 13.33.1. Antibiotic 13.33.2. Antifungal 13.33.3. Others 13.34. Spain Gram Positive Bacterial Infections Market Forecast, Route of Administration 13.34.1. Enteral 13.34.2. Parenteral 13.35. Spain Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 13.35.1. Hospital Pharmacies 13.35.2. Drug Stores 13.35.3. Retail Pharmacies 13.36. Rest of Europe Gram Positive Bacterial Infections Market Forecast, by Disease 13.36.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 13.36.2. Pneumonia 13.36.3. Sepsis 13.36.4. Sinusitis 13.36.5. Cellulitis 13.36.6. Otitis 13.36.7. Pharyngitis 13.36.8. Impetigo 13.37. Rest of Europe Gram Positive Bacterial Infections Market Forecast, by Drug Type 13.37.1. Antibiotic 13.37.2. Antifungal 13.37.3. Others 13.38. Rest of Europe Gram Positive Bacterial Infections Market Forecast, Route of Administration 13.38.1. Enteral 13.38.2. Parenteral 13.39. Rest Of Europe Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 13.39.1. Hospital Pharmacies 13.39.2. Drug Stores 13.39.3. Retail Pharmacies 13.40. Europe Gram Positive Bacterial Infections Market Attractiveness Analysis 13.40.1. By Disease 13.40.2. By Drug Type 13.40.3. Route of Administration 13.40.4. By Distribution Channel 13.41. PEST Analysis 13.42. Key Trends 13.43. Key Developments 14. Asia Pacific Gram Positive Bacterial Infections Market Analysis 14.1. Key Findings 14.2. Asia Pacific Gram Positive Bacterial Infections Market Overview 14.3. Asia Pacific Gram Positive Bacterial Infections Market Value Share Analysis, by Disease 14.4. Asia Pacific Gram Positive Bacterial Infections Market Forecast, by Disease 14.4.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 14.4.2. Pneumonia 14.4.3. Sepsis 14.4.4. Sinusitis 14.4.5. Cellulitis 14.4.6. Otitis 14.4.7. Pharyngitis 14.4.8. Impetigo 14.5. Asia Pacific Gram Positive Bacterial Infections Market Value Share Analysis, by Drug Type 14.6. Asia Pacific Gram Positive Bacterial Infections Market Forecast, by Drug Type 14.6.1. Antibiotic 14.6.2. Antifungal 14.6.3. Others 14.7. Asia Pacific Gram Positive Bacterial Infections Market Value Share Analysis, Route of Administration 14.8. Asia Pacific Gram Positive Bacterial Infections Market Forecast, Route of Administration 14.8.1. Enteral 14.8.2. Parenteral 14.9. Asia Pacific Gram Positive Bacterial Infections Market Value Share Analysis, by Distribution Channel 14.10. Asia Pacific Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 14.10.1. Hospital Pharmacies 14.10.2. Drug Stores 14.10.3. Retail Pharmacies 14.11. Asia Pacific Gram Positive Bacterial Infections Market Value Share Analysis, by Country 14.12. Asia Pacific Gram Positive Bacterial Infections Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Gram Positive Bacterial Infections Market Analysis, by Country 14.14. China Gram Positive Bacterial Infections Market Forecast, by Disease 14.14.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 14.14.2. Pneumonia 14.14.3. Sepsis 14.14.4. Sinusitis 14.14.5. Cellulitis 14.14.6. Otitis 14.14.7. Pharyngitis 14.14.8. Impetigo 14.15. China Gram Positive Bacterial Infections Market Forecast, by Drug Type 14.15.1. Antibiotic 14.15.2. Antifungal 14.15.3. Others 14.16. China Gram Positive Bacterial Infections Market Forecast, Route of Administration 14.16.1. Enteral 14.16.2. Parenteral 14.17. China Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Drug Stores 14.17.3. Retail Pharmacies 14.18. India Gram Positive Bacterial Infections Market Forecast, by Disease 14.18.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 14.18.2. Pneumonia 14.18.3. Sepsis 14.18.4. Sinusitis 14.18.5. Cellulitis 14.18.6. Otitis 14.18.7. Pharyngitis 14.18.8. Impetigo 14.19. India Gram Positive Bacterial Infections Market Forecast, by Drug Type 14.19.1. Antibiotic 14.19.2. Antifungal 14.19.3. Others 14.20. India Gram Positive Bacterial Infections Market Forecast, Route of Administration 14.20.1. Enteral 14.20.2. Parenteral 14.21. India Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 14.21.1. Hospital Pharmacies 14.21.2. Drug Stores 14.21.3. Retail Pharmacies 14.22. Japan Gram Positive Bacterial Infections Market Forecast, by Disease 14.22.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 14.22.2. Pneumonia 14.22.3. Sepsis 14.22.4. Sinusitis 14.22.5. Cellulitis 14.22.6. Otitis 14.22.7. Pharyngitis 14.22.8. Impetigo 14.23. Japan Gram Positive Bacterial Infections Market Forecast, by Drug Type 14.23.1. Antibiotic 14.23.2. Antifungal 14.23.3. Others 14.24. Japan Gram Positive Bacterial Infections Market Forecast, Route of Administration 14.24.1. Enteral 14.24.2. Parenteral 14.25. Japan Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 14.25.1. Hospital Pharmacies 14.25.2. Drug Stores 14.25.3. Retail Pharmacies 14.26. ASEAN Gram Positive Bacterial Infections Market Forecast, by Disease 14.26.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 14.26.2. Pneumonia 14.26.3. Sepsis 14.26.4. Sinusitis 14.26.5. Cellulitis 14.26.6. Otitis 14.26.7. Pharyngitis 14.26.8. Impetigo 14.27. ASEAN Gram Positive Bacterial Infections Market Forecast, by Drug Type 14.27.1. Antibiotic 14.27.2. Antifungal 14.27.3. Others 14.28. ASEAN Gram Positive Bacterial Infections Market Forecast, Route of Administration 14.28.1. Enteral 14.28.2. Parenteral 14.29. ASEAN Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 14.29.1. Hospital Pharmacies 14.29.2. Drug Stores 14.29.3. Retail Pharmacies 14.30. Rest of Asia Pacific Gram Positive Bacterial Infections Market Forecast, by Disease 14.30.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 14.30.2. Pneumonia 14.30.3. Sepsis 14.30.4. Sinusitis 14.30.5. Cellulitis 14.30.6. Otitis 14.30.7. Pharyngitis 14.30.8. Impetigo 14.31. Rest of Asia Pacific Gram Positive Bacterial Infections Market Forecast, by Drug Type 14.31.1. Antibiotic 14.31.2. Antifungal 14.31.3. Others 14.32. Rest of Asia Pacific Gram Positive Bacterial Infections Market Forecast, Route of Administration 14.32.1. Enteral 14.32.2. Parenteral 14.33. Rest of Asia Pacific Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 14.33.1. Hospital Pharmacies 14.33.2. Drug Stores 14.33.3. Retail Pharmacies 14.34. Asia Pacific Gram Positive Bacterial Infections Market Attractiveness Analysis 14.34.1. By Disease 14.34.2. By Drug Type 14.34.3. Route of Administration 14.34.4. By Distribution Channel 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Gram Positive Bacterial Infections Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Gram Positive Bacterial Infections Market Overview 15.3. Middle East & Africa Gram Positive Bacterial Infections Market Value Share Analysis, by Disease 15.4. Middle East & Africa Gram Positive Bacterial Infections Market Forecast, by Disease 15.4.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 15.4.2. Pneumonia 15.4.3. Sepsis 15.4.4. Sinusitis 15.4.5. Cellulitis 15.4.6. Otitis 15.4.7. Pharyngitis 15.4.8. Impetigo 15.5. Middle East & Africa Gram Positive Bacterial Infections Market Value Share Analysis, by Drug Type 15.6. Middle East & Africa Gram Positive Bacterial Infections Market Forecast, by Drug Type 15.6.1. Antibiotic 15.6.2. Antifungal 15.6.3. Others 15.7. Middle East & Africa Gram Positive Bacterial Infections Market Value Share Analysis, Route of Administration 15.8. Middle East & Africa Gram Positive Bacterial Infections Market Forecast, Route of Administration 15.8.1. Enteral 15.8.2. Parenteral 15.9. Middle East & Africa Gram Positive Bacterial Infections Market Value Share Analysis, by Distribution Channel 15.10. Middle East & Africa Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 15.10.1. Hospital Pharmacies 15.10.2. Drug Stores 15.10.3. Retail Pharmacies 15.11. Middle East & Africa Gram Positive Bacterial Infections Market Value Share Analysis, by Country 15.12. Middle East & Africa Gram Positive Bacterial Infections Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Gram Positive Bacterial Infections Market Analysis, by Country 15.14. GCC Gram Positive Bacterial Infections Market Forecast, by Disease 15.14.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 15.14.2. Pneumonia 15.14.3. Sepsis 15.14.4. Sinusitis 15.14.5. Cellulitis 15.14.6. Otitis 15.14.7. Pharyngitis 15.14.8. Impetigo 15.15. GCC Gram Positive Bacterial Infections Market Forecast, by Drug Type 15.15.1. Antibiotic 15.15.2. Antifungal 15.15.3. Others 15.16. GCC Gram Positive Bacterial Infections Market Forecast, Route of Administration 15.16.1. Enteral 15.16.2. Parenteral 15.17. GCC Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Drug Stores 15.17.3. Retail Pharmacies 15.18. South Africa Gram Positive Bacterial Infections Market Forecast, by Disease 15.18.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 15.18.2. Pneumonia 15.18.3. Sepsis 15.18.4. Sinusitis 15.18.5. Cellulitis 15.18.6. Otitis 15.18.7. Pharyngitis 15.18.8. Impetigo 15.19. South Africa Gram Positive Bacterial Infections Market Forecast, by Drug Type 15.19.1. Antibiotic 15.19.2. Antifungal 15.19.3. Others 15.20. South Africa Gram Positive Bacterial Infections Market Forecast, Route of Administration 15.20.1. Enteral 15.20.2. Parenteral 15.21. South Africa Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 15.21.1. Hospital Pharmacies 15.21.2. Drug Stores 15.21.3. Retail Pharmacies 15.22. Rest of Middle East & Africa Gram Positive Bacterial Infections Market Forecast, by Disease 15.22.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 15.22.2. Pneumonia 15.22.3. Sepsis 15.22.4. Sinusitis 15.22.5. Cellulitis 15.22.6. Otitis 15.22.7. Pharyngitis 15.22.8. Impetigo 15.23. Rest of Middle East & Africa Gram Positive Bacterial Infections Market Forecast, by Drug Type 15.23.1. Antibiotic 15.23.2. Antifungal 15.23.3. Others 15.24. Rest of Middle East & Africa Gram Positive Bacterial Infections Market Forecast, Route of Administration 15.24.1. Enteral 15.24.2. Parenteral 15.25. Rest of Middle East & Africa Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 15.25.1. Hospital Pharmacies 15.25.2. Drug Stores 15.25.3. Retail Pharmacies 15.26. Middle East & Africa Gram Positive Bacterial Infections Market Attractiveness Analysis 15.26.1. By Disease 15.26.2. By Drug Type 15.26.3. Route of Administration 15.26.4. By Distribution Channel 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Gram Positive Bacterial Infections Market Analysis 16.1. Key Findings 16.2. South America Gram Positive Bacterial Infections Market Overview 16.3. South America Gram Positive Bacterial Infections Market Value Share Analysis, by Disease 16.4. South America Gram Positive Bacterial Infections Market Forecast, by Disease 16.4.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 16.4.2. Pneumonia 16.4.3. Sepsis 16.4.4. Sinusitis 16.4.5. Cellulitis 16.4.6. Otitis 16.4.7. Pharyngitis 16.4.8. Impetigo 16.5. South America Gram Positive Bacterial Infections Market Value Share Analysis, by Drug Type 16.6. South America Gram Positive Bacterial Infections Market Forecast, by Drug Type 16.6.1. Antibiotic 16.6.2. Antifungal 16.6.3. Others 16.7. South America Gram Positive Bacterial Infections Market Value Share Analysis, Route of Administration 16.8. South America Gram Positive Bacterial Infections Market Forecast, Route of Administration 16.8.1. Enteral 16.8.2. Parenteral 16.9. South America Gram Positive Bacterial Infections Market Value Share Analysis, by Distribution Channel 16.10. South America Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 16.10.1. Hospital Pharmacies 16.10.2. Drug Stores 16.10.3. Retail Pharmacies 16.11. South America Gram Positive Bacterial Infections Market Value Share Analysis, by Country 16.12. South America Gram Positive Bacterial Infections Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Gram Positive Bacterial Infections Market Analysis, by Country 16.14. Brazil Gram Positive Bacterial Infections Market Forecast, by Disease 16.14.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 16.14.2. Pneumonia 16.14.3. Sepsis 16.14.4. Sinusitis 16.14.5. Cellulitis 16.14.6. Otitis 16.14.7. Pharyngitis 16.14.8. Impetigo 16.15. Brazil Gram Positive Bacterial Infections Market Forecast, by Drug Type 16.15.1. Antibiotic 16.15.2. Antifungal 16.15.3. Others 16.16. Brazil Gram Positive Bacterial Infections Market Forecast, Route of Administration 16.16.1. Enteral 16.16.2. Parenteral 16.17. Brazil Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 16.17.1. Hospital Pharmacies 16.17.2. Drug Stores 16.17.3. Retail Pharmacies 16.18. Mexico Gram Positive Bacterial Infections Market Forecast, by Disease 16.18.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 16.18.2. Pneumonia 16.18.3. Sepsis 16.18.4. Sinusitis 16.18.5. Cellulitis 16.18.6. Otitis 16.18.7. Pharyngitis 16.18.8. Impetigo 16.19. Mexico Gram Positive Bacterial Infections Market Forecast, by Drug Type 16.19.1. Antibiotic 16.19.2. Antifungal 16.19.3. Others 16.20. Mexico Gram Positive Bacterial Infections Market Forecast, Route of Administration 16.20.1. Enteral 16.20.2. Parenteral 16.21. Mexico Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 16.21.1. Hospital Pharmacies 16.21.2. Drug Stores 16.21.3. Retail Pharmacies 16.22. Rest of South America Gram Positive Bacterial Infections Market Forecast, by Disease 16.22.1. (MRSA) Methicillin Resistant Staphylococcus Aureus 16.22.2. Pneumonia 16.22.3. Sepsis 16.22.4. Sinusitis 16.22.5. Cellulitis 16.22.6. Otitis 16.22.7. Pharyngitis 16.22.8. Impetigo 16.23. Rest of South America Gram Positive Bacterial Infections Market Forecast, by Drug Type 16.23.1. Antibiotic 16.23.2. Antifungal 16.23.3. Others 16.24. Rest of South America Gram Positive Bacterial Infections Market Forecast, Route of Administration 16.24.1. Enteral 16.24.2. Parenteral 16.25. Rest of South America Gram Positive Bacterial Infections Market Forecast, by Distribution Channel 16.25.1. Hospital Pharmacies 16.25.2. Drug Stores 16.25.3. Retail Pharmacies 16.26. South America Gram Positive Bacterial Infections Market Attractiveness Analysis 16.26.1. By Disease 16.26.2. By Drug Type 16.26.3. Route of Administration 16.26.4. By Distribution Channel 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. ALLERGAN 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Company Footprint 17.3.2. AstraZeneca 17.3.3. Bayer AG 17.3.4. GlaxoSmithkline plc. 17.3.5. Merck & Co.,Inc. 17.3.6. NovaBiotics Ltd 17.3.7. Novartis AG 17.3.8. Pfizer Inc. 17.3.9. Sanofi 17.3.10. Theravance Biopharma 17.3.11. Bristol-Myers Squibb Company 18. Primary Key Insights